Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
13
9
10
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+33 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (13)
Showing 10 of 13 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Nai-Kong V. Cheung, MD, PhD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Shakeel Modak, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Trudy N. Small, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Vincenzo Liso, MD
UO Universita degi Studi Policinico Ematologia
Shared therapeutic areas:
Worked with same sponsors:
Wendy Stock, MD
University of Chicago Hospital
Shared therapeutic areas:
Worked with same sponsors:
Vernon Louw, MD
Free State University
Shared therapeutic areas:
Worked with same sponsors:
Gary Schiller, MD
University of California, Los Angeles
Shared therapeutic areas:
Worked with same sponsors:
Peter Staib, MD
Med. Klinik I / Hamatolgie
Shared therapeutic areas:
Worked with same sponsors:
Nicholas Novitzky, MD
Division of Haematology
Shared therapeutic areas:
Worked with same sponsors:
Gerhard Ehninger, MD
Klinikum Carl Gustav Carus der Technischen Universitat
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (13)
Showing 13 of 13 trials
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
All 13 trials loaded